Ridinilazole

  • CAT Number: I009036
  • CAS Number: 308362-25-6
  • Molecular Formula: C24H16N6
  • Molecular Weight: 388.43
  • Purity: ≥95%
Inquiry Now

Ridinilazole(Cat No.:I009036), also known as SMT-19969, is a novel narrow-spectrum nonabsorbable antibiotic currently in development for the treatment of Clostridium difficile infection. SMT19969 is highly effective at treating both acute infection and preventing recurrent disease and support continued investigation of SMT19969 as a potential therapy for CDI.

Catalog Number I009036
CAS Number 308362-25-6
Synonyms

SMT-19969; SMT 19969; SMT19969; Ridinilazole;2,2/’-di(pyridin-4-yl)-1H,1/’H-5,5/’-bi(benzimidazole)

Molecular Formula

C24H16N6

Purity 95%
Solubility Soluble in DMSO, not in water
Storage Store at -20°C
IUPAC Name 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole
InChI InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
InChIKey UHQFBTAJFNVZIV-UHFFFAOYSA-N
SMILES C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6
Reference

</br>1:Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Vickers RJ, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFy study group..Lancet Infect Dis. 2017 Apr 28. pii: S1473-3099(17)30235-9. doi: 10.1016/S1473-3099(17)30235-9. [Epub ahead of print] PMID: 28461207 Free Article</br>2:Ridinilazole: a novel therapy for Clostridium difficile infection. Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH.Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Review. PMID: 27283730 Free Article</br>3:Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW.J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. Epub 2016 Feb 18. PMID: 26895772 Free PMC Article

Request a Quote